Research programme: neutralising anti-COVID-2019 antibodies - Entos Pharmaceuticals
Latest Information Update: 01 Apr 2021
At a glance
- Originator Entos Pharmaceuticals
- Class Antibodies; Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 03 Mar 2021 Neutralising anti-COVID-2019 antibodies - Entos Pharmaceuticals is available for licensing as of 03 Mar 2021. https://www.entospharma.com/fusogenix
- 03 Mar 2021 Preclinical trials in COVID-2019 infections in Canada (Parenteral)